Market Analysis
Product Positioning
Competitor Monitoring
Find Global Buyers
Find Contact Information
Company Comparison
Supply Chain Optimization
Email Marketing
Customer Management
Blog
FAQs
About Topease
Agency Program
UzbekistanNovugen Pharma FE LLC is the Uzbekistan-based manufacturing subsidiary of Novugen Pharma, a pharmaceutical company and wholly owned subsidiary of the UAE-based SciTech International group. Located in Tashkent, Uzbekistan, the facility was acquired by the Novugen group in 2019 and revamped to comply with current good manufacturing practices (cGMP) to serve the CIS and Eurasian markets. The plant manufactures finished dose pharmaceutical products developed at Novugen's global R&D centre in Malaysia and has launched over 25 products across major therapeutic areas. It operates as a general pharmaceutical manufacturing facility accredited by the Center for Pharmaceutical Products Safety under the Ministry of Health of the Republic of Uzbekistan.
| Import | Export |
|---|---|
|
Trade Records
247
|
Trade Records
122
|
|
Suppliers
4
|
Buyers
2
|
|
Latest Import Date
2026-07
|
Latest Export Date
2026-06
|
According to Topease's global trade data, ИП ООО "NOVUGEN PHARMA" exports products to verified importers across global markets.
Its export activity is associated with HS-code categories such as:
Representative importers include:
These export insights help users understand the ИП ООО "NOVUGEN PHARMA" distribution footprint, product specialization, and shipment scale. Through Topease's deep trade data and trade intelligence capabilities—such as trade flow analysis and market benchmarking—importers and exporters can evaluate downstream demand and identify potential importer relationships.
As an importer, ИП ООО "NOVUGEN PHARMA" sources products from verified exporters across multiple regions.
Its import activity spans HS-code categories including:
Representative exporters include:
These import insights help users assess sourcing patterns, supplier concentration, and trade continuity. With Topease's analytical tools—such as sourcing pattern analysis and supply-chain mapping—users can evaluate supplier performance and identify diversification opportunities.
Explore ИП ООО "NOVUGEN PHARMA"'s import activity, including trade volumes, top suppliers, sourcing countries, and key product categories. These insights allow exporters and potential suppliers to understand its global supply chains, track procurement trends, and identify new business opportunities.
| Exporter | Importer | HS Code | Number of Trade | Amount (USD) | Quantity | Import Port |
|---|---|---|---|---|---|---|
| ADCHEM INTERNATIONAL FZCO | ИП ООО "NOVUGEN PHARMA" | 3912 | 24 | $186,500 | 3,420 | Los Angeles |
| ONYX PHARMA LTD-АФГАНИСТАН | ИП ООО "NOVUGEN PHARMA" | 3004 | 24 | $186,500 | 3,420 | Los Angeles |
| M S NISSO SHOJI CO LTD | ИП ООО "NOVUGEN PHARMA" | 3912 | 24 | $186,500 | 3,420 | Los Angeles |
| COSHINE INTERNATIONAL LIMITED-ГОНКОНГ | ИП ООО "NOVUGEN PHARMA" | 2936 | 24 | $186,500 | 3,420 | Los Angeles |
Gain insights into ИП ООО "NOVUGEN PHARMA"'s export activities, including shipment volumes, key buyers, destination countries, and product categories. Understand global demand patterns, track sales reach, and spot opportunities to connect with potential buyers.
| Importer | Exporter | HS Code | Number of Trade | Amount (USD) | Quantity | Export Port |
|---|---|---|---|---|---|---|
| ONYX PHARMA LTD | ИП ООО "NOVUGEN PHARMA" | 3004 | 24 | $186,500 | 3,420 | Los Angeles |
| LLC MUHAMMAD-A | ИП ООО "NOVUGEN PHARMA" | 3004 | 24 | $186,500 | 3,420 | Los Angeles |
Chain Insights — Explore ИП ООО "NOVUGEN PHARMA"'s trading network to uncover connections with international buyers and suppliers. With Topease's Supply Chain Solution, you can track product flows and identify patterns that reveal new sourcing and partnership opportunities.
Access ИП ООО "NOVUGEN PHARMA"'s key professional contacts for B2B outreach purposes. View verified phone numbers, emails, and LinkedIn profiles to facilitate efficient business communication.
Disclaimer: Data is compiled from public and third-party sources and may not be complete or fully accurate. This information is provided for business intelligence purposes only and should not be used for legal, financial, or compliance decisions.